Vitamin D: An instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression

Annals of the Rheumatic Diseases

Volumn 70, Issue 1, 2011, Pages 145-150

  Agmon Levin, N ^a   Blank, M ^a   Zandman Goddard, G ^b,c   Orbach, H ^b,c   Meroni, P L ^d   Tincani, A ^e   Doria, A ^f   Cervera, R ^g   Miesbach, W ^h   Stojanovich, L ⁱ   Barak, V ^j   Porat Katz, B S ^k   Amital, H ^c   Shoenfeld, Y ^a,c  

^a SHEBA MEDICAL CENTER   (Israel)

^b Wolfson Medical Centre   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF BRESCIA   (Italy)

^f UNIVERSITY OF PADOVA   (Italy)

^g HOSPITAL CLÍNIC   (Spain)

^h GOETHE UNIVERSITY   (Germany)

ⁱ UNIVERSITY OF BELGRADE   (Serbia)

^j HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^k HEBREW UNIVERSITY OF JERUSALEM   (Israel)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; THROMBOPLASTIN; VITAMIN D;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD CLOTTING; CHEMOLUMINESCENCE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; EYE DISEASE; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; LIVEDO RETICULARIS; MAJOR CLINICAL STUDY; MALE; NEUROLOGICAL COMPLICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; SKIN ULCER; THROMBOSIS; VITAMIN D DEFICIENCY;

ADULT; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; CASE-CONTROL STUDIES; CELLS, CULTURED; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; MIDDLE AGED; THROMBOPLASTIN; THROMBOSIS; VITAMIN D; VITAMIN D DEFICIENCY; VITAMINS;

EID: 78650676621     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.134817     Document Type: Article

References (42)

1. Arnson Y, Amital H, Shoenfeld Y. Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis 2007 ; 66 : 1137-42.
2. Shapira Y, Agmon-Levin N, Shoenfeld Y. Mycobacterium tuberculosis, autoimmunity, and vitamin D. Clin Rev Allergy Immunol 2010 ; 38 : 169-77.
3. Giovannucci E, Liu Y, Rimm EB, et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 2006 ; 98 : 451-9.
4. Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008 ; 117 : 503-11.
5. Giovannucci E. Epidemiological evidence for vitamin D and colorectal cancer. J Bone Miner Res 2007 ; 22 : V81 - 5.
6. Giovannucci E. Can vitamin D reduce total mortality? Arch Intern Med 2007 ; 167 : 1709-10.
7. Grant WB, Cross HS, Garland CF, et al. Estimated benefit of increased vitamin D status in reducing the economic burden of disease in western Europe. Prog Biophys Mol Biol 2009 ; 99 : 104-13.
8. Deluca HF, Cantorna MT. Vitamin D: its role and uses in immunology. FASEB J 2001 ; 15 : 2579-85.
9. Adorini L, Penna G, Giarratana N, et al. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases. J Cell Biochem 2003 ; 88 : 227-33. (Pubitemid 36119891)
10. Shoenfeld N, Amital H, Shoenfeld Y. The effect of melanism and vitamin D synthesis on the incidence of autoimmune disease. Nat Clin Pract Rheumatol 2009 ; 5 : 99-105.
11. Carvalho JF, Blank M, Kiss E, et al. Anti-vitamin D, vitamin D in SLE: preliminary results. Ann N Y Acad Sci 2007 ; 1109 : 550-7.
12. Orbach H, Zandman-Goddard G, Amital H, et al. Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases. Ann N Y Acad Sci 2007 ; 1109 : 385-400.
13. Amital H, Szekanecz Z, Szücs G. Serum concentrations of 25-OH Vitamin D in SLE patients are inversely related to disease activity- is it time to routinely supplement SLE patients with vitamin D? Ann Rheum Dis 2010 ; 69 : 1155-7.
14. Toloza SM, Cole DE, Gladman DD, et al. Vitamin D insufficiency in a large female SLE cohort. Lupus 2010 ; 19 : 13 - 19.
15. Borba VZ, Vieira JG, Kasamatsu T, et al. Vitamin D deficiency in patients with active systemic lupus erythematosus. Osteoporos Int 2009 ; 20 : 427-33.
16. Hyppönen E, Läärä E, Reunanen A, et al. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001 ; 358 : 1500-3.
17. Merlino LA, Curtis J, Mikuls TR, et al. Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study. Arthritis Rheum 2004 ; 50 : 72-7.
18. Munger KL, Levin LI, Hollis BW, et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006 ; 296 : 2832-8.
19. Goswami R, Marwaha RK, Gupta N, et al. P revalence of vitamin D deficiency and its relationship with thyroid autoimmunity in Asian Indians: a community-based survey. Br J Nutr 2009 ; 10 : 1-5.
20. Pierangeli SS, Chen PP, Raschi E, et al. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost 2008 ; 34 : 236-50.
21. Kornberg A, Blank M, Kaufman S, et al. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol 1994 ; 153 : 1328-32.
22. Ostertag MV, Liu X, Kwan-Ki H, et al. A human monoclonal antiprothrombin antibody is thrombogenic in vivo and upregulates expression of tissue factor and E-selectin on endothelial cells. BJH 2006 ; 135 : 214-19.
23. Hughes G. Hughes Syndrome: the antiphospholipid syndrome-a clinical overview. Clin Rev Allergy Immunol 2007 ; 32 : 3-12.
24. Ersfeld DL, Rao DS, Body JJ, et al. Analytical and clinical validation of the 25 OH vitamin D assay for the LIAISON automated analyzer. Clin Biochem 2004 ; 37 : 867-74.
25. Dawson-Hughes B, Heaney RP, Holick MF, et al. Estimates of optimal vitamin D status. Osteoporos Int 2005 ; 16 : 713-16.
26. Chesney RW. Vitamin D and The Magic Mountain: the anti-infectious role of the vitamin. J Pediatr 2010 ; 156 : 698-703.
27. Holick MF. Vitamin D status: measurement, interpretation, and clinical application. Ann Epidemiol 2009 ; 19 : 73-8.
28. Tomer Y, Blank M, Shoenfeld Y. Suppression of experimental antiphospholipid syndrome and systemic lupus erythematosus in mice by anti-CD4 monoclonal antibodies. Arthritis Rheum 1994 ; 37 : 1236-44. (Pubitemid 24313326)
29. Dodd RC, Cohen MS, Newman SL, et al. Vitamin D metabolites change the phenotype of monoblastic U937 cells. Proc Natl Acad Sci USA 1983 ; 80 : 7538-41.
30. Wiese RJ, Uhland-Smith A, Ross TK, et al. Up-regulation of the vitamin D receptor in response to 1,25-dihydroxyvitamin D3 results from ligand-induced stabilization. J Biol Chem 1992 ; 267 : 20082-6.
31. Cutolo M, Otsa K, Paolino S, et al. Vitamin D involvement in rheumatoid arthritis and systemic lupus erythaematosus. Ann Rheum Dis 2009 ; 68 : 446-7.
32. Toubi E, Shoenfeld Y. Livedo reticularis as a criterion for antiphospholipid syndrome. Clin Rev Allergy Immunol 2007 ; 32 : 138-44.
33. Lindqvist PG, Epstein E, Olsson H. Does an active sun exposure habit lower the risk of venous thrombotic events? A D-lightful hypothesis. J Thromb Haemost 2009; 7 : 605-10.
34. Beer TM, Venner PM, Ryan CW, et al. High dose calcitriol may reduce thrombosis in cancer patients. Br J Haematol 2006 ; 135 : 392-4.
35. Pierangeli S S, Vega-Ostertag ME, González EB. New targeted therapies for treatment of thrombosis in antiphospholipid syndrome. Expert Rev Mol Med 2007 ; 9 : 1-15.
36. Ruiz-Irastorza G, Egurbide MV, Olivares N, et al. Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology (Oxford) 2008 ; 47 : 920-3.
37. Ohsawa M, Koyama T, Yamamoto K, et al. 1alpha,25-dihydroxyvitamin D(3) and its potent synthetic analogs downregulate tissue factor and upregulate thrombomodulin expression in monocytic cells, counteracting the effects of tumor necrosis factor and oxidized LDL. Circulation 2000 ; 102 : 2867-72.
38. Chung J, Koyama T, Ohsawa M, et al. 1,25(OH)(2)D(3) blocks TNF-induced monocytic tissue factor expression by inhibition of transcription factors AP-1 and NF-kappaB. Lab Invest 2007 ; 87 : 540-7.
39. Pierangeli SS, Vega-Ostertag ME, Raschi E, et al. Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. Ann Rheum Dis 2007; 66 : 1327-33.
40. Raschi E, Borghi MO, Grossi C, et al. Toll-like receptors: another player in the pathogenesis of the anti-phospholipid syndrome. Lupus 2008 ; 17 : 937-42.
41. Mantell DJ, Owens PE, Bundred NJ, et al. 1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res 2000 ; 87 : 214-20.
42. Sadeghi K, Wessner B, Laggner U, et al. Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur J Immunol 2006 ; 36 : 361-70.